Targeted proteomics reveals novel biomarkers of disease activity and inflammation in acromegaly
Authors' conclusion
Acromegaly is associated with changes in ECM remodeling and inflammation. Several proteins were linked to disease activity, with glial cell derived neurotrophic factor and insulin like growth factor binding protein 2 serving as promising plasma biomarkers with potential to further optimize management of disease.
Study context
- Population
- Patients diagnosed with acromegaly; sub-cohort received primary somatostatin receptor ligand (SRL) treatment before surgerySRL sub-cohort n = 14
- Participants
- 37 patients
- Comparison
- Before vs after disease control by surgery
- Outcome
- Plasma proteins (184) before vs after disease control by surgery
Methodological detailstargeted proteomics, Olink Target 96 Cardiovascular III and Inflammation panels, Enzyme Immunoassay (EIA) validation, Eight proteins validated by EIA, DXA and biochemical measurements at all visits, Plasma samples at baseline, preoperative medical treatment and postoperative visits
- Targeted proteomics
- Olink Target 96 Cardiovascular III and Inflammation panels
- EIA validation
- Eight proteins validated by EIA
- DXA and biochemical measurements at all visits
- Plasma samples at baseline, preoperative medical treatment and postoperative visits
Main finding
As reported in the abstract
Proteins significantly differentially expressed (P-adjusted < .05)
37
Enrichment analyses: clusters, extracellular matrix (ECM) remodeling and inflammation most prominent
5
Proteins with temporal change with SRL treatment
5
Original publication
Targeted proteomics reveals novel biomarkers of disease activity and inflammation in acromegaly. Eur J Endocrinol. Published 12 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →